carbacitabine

Carbacitabine is a novel small molecule analogue of decitabine (5-aza-2'-deoxycytidine) that functions as a DNA methyltransferase (DNMT) inhibitor and hypomethylating agent. Developed for the treatment of acute myeloid leukemia (AML), it is designed to offer enhanced anti-leukemic activity and a significantly improved safety profile compared to standard therapies like decitabine and azacitidine. Preclinical studies in patient-derived xenograft (PDX) models have demonstrated that carbacitabine induces higher levels of apoptosis and can overcome resistance to existing hypomethylating agents. Furthermore, it exhibits markedly reduced hematotoxicity, allowing for a therapeutic window up to 100-fold wider than that of decitabine in vivo.